- Home
- TVTX
as of 12-05-2025 3:45pm EST
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
| Founded: | 2008 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 3.1B | IPO Year: | N/A |
| Target Price: | $37.21 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.91 - $37.50 | Next Earning Date: | 10-30-2025 |
| Revenue: | $435,826,000 | Revenue Growth: | 114.22% |
| Revenue Growth (this year): | 120.36% | Revenue Growth (next year): | 37.33% |
AI-Powered TVTX Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Travere Therapeutics Inc. (TVTX)
CHIEF FINANCIAL OFFICER
Avg Cost/Share
$35.01
Shares
20,000
Total Value
$700,202.00
Owned After
92,083
SEC Form 4
SVP, CHIEF ACCOUNTING OFFICER
Avg Cost/Share
$36.00
Shares
67,115
Total Value
$2,416,140.00
Owned After
48,545
SEC Form 4
CHIEF COMMERCIAL OFFICER
Avg Cost/Share
$35.00
Shares
5,591
Total Value
$195,685.00
Owned After
119,071
SEC Form 4
Director
Avg Cost/Share
$35.03
Shares
18,000
Total Value
$630,601.20
Owned After
55,500
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$30.12
Shares
27,128
Total Value
$817,073.66
Owned After
419,173
SEC Form 4
CHIEF EXECUTIVE OFFICER
Avg Cost/Share
$30.38
Shares
92,872
Total Value
$2,821,358.49
Owned After
419,173
SEC Form 4
CHIEF COMMERCIAL OFFICER
Avg Cost/Share
$30.00
Shares
2,662
Total Value
$79,860.00
Owned After
119,071
SEC Form 4
Chief Legal Officer and GC
Avg Cost/Share
$25.00
Shares
10,000
Total Value
$250,000.00
Owned After
89,878
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Cline Christopher R. | TVTX | CHIEF FINANCIAL OFFICER | Dec 1, 2025 | Sell | $35.01 | 20,000 | $700,202.00 | 92,083 | |
| Calvin Sandra | TVTX | SVP, CHIEF ACCOUNTING OFFICER | Nov 4, 2025 | Sell | $36.00 | 67,115 | $2,416,140.00 | 48,545 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Oct 31, 2025 | Sell | $35.00 | 5,591 | $195,685.00 | 119,071 | |
| COUGHLIN TIMOTHY | TVTX | Director | Oct 31, 2025 | Sell | $35.03 | 18,000 | $630,601.20 | 55,500 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Oct 29, 2025 | Sell | $30.12 | 27,128 | $817,073.66 | 419,173 | |
| Dube Eric M | TVTX | CHIEF EXECUTIVE OFFICER | Oct 28, 2025 | Sell | $30.38 | 92,872 | $2,821,358.49 | 419,173 | |
| Heerma Peter | TVTX | CHIEF COMMERCIAL OFFICER | Oct 28, 2025 | Sell | $30.00 | 2,662 | $79,860.00 | 119,071 | |
| REED ELIZABETH E | TVTX | Chief Legal Officer and GC | Sep 22, 2025 | Sell | $25.00 | 10,000 | $250,000.00 | 89,878 |
Compare TVTX vs Leading Stocks
See how TVTX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TVTX Travere Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.